David Braun, MD, PhD, on the Unique Experiences at IKCS

Article

The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.

David Braun, MD, PhD, from Dana-Farber Cancer Institute, discussed the integration of fields and how they yield a unique experience at the International Kidney Cancer Symposium, held November 15-16, in Miami.

Transcription:
I mean, there’s a lot. I would say, so there’s incredibly interesting clinical work, there’s incredibly interesting scientific work. Honestly the most exciting thing for me has been the integration of everyone. Seeing people who are just master clinicians, people who are, you know, dedicated to their lab work and are pure scientists, people who are patient advocates who are obviously passionate and have personal experience, and seeing everyone in the same room together, I think that’s a unique experience. That’s really made this a special meeting.

Recent Videos
Blood-based markers of note in kidney cancer prognosis include circulating tumor DNA and proteomic markers, according to Michael B. Atkins, MD.
Clinical trials still have a role in improving outcomes with immunotherapy among those with kidney cancer.
Current research initiatives in the kidney cancer field include exploring anti–PD-1, anti–LAG-3, and anti–CTLA-4 combination regimens.
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Related Content